K
Kristine Rose
Researcher at Novartis
Publications - 15
Citations - 1642
Kristine Rose is an academic researcher from Novartis. The author has contributed to research in topics: Sonidegib & Cancer. The author has an hindex of 10, co-authored 15 publications receiving 1513 citations.
Papers
More filters
Journal ArticleDOI
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Wolfgang Hueber,Dhavalkumar D. Patel,Thaddeus P. Dryja,Andrew M Wright,Irina Koroleva,Gerard Bruin,Christian Antoni,Zoe Diana Draelos,Michael H. Gold,Patrick Durez,Paul P. Tak,Juan J. Gomez-Reino,C. Stephen Foster,Rosa Y. Kim,C. Michael Samson,Naomi S. Falk,David S. Chu,David Callanan,Quan Dong Nguyen,Kristine Rose,Asifa Haider,Franco Di Padova +21 more
TL;DR: The results demonstrate that IL-17A participates in psoriasis, rheumatoid arthritis, and uveitis and that the antibody against this cytokine may be an effective therapeutic agent, and warrant larger clinical trials to assess further the safety and efficacy of AIN457.
Journal ArticleDOI
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors
Jordi Rodon,Hussein Tawbi,Anne L. Thomas,Ronald G. Stoller,Christian P. Turtschi,José Baselga,John Sarantopoulos,Devalingam Mahalingam,Yaping Shou,Melissa A. Moles,Lin Yang,Camille Granvil,Eunju Hurh,Kristine Rose,Dereck Amakye,Reinhard Dummer,Alain C. Mita +16 more
TL;DR: Sonidegib has an acceptable safety profile in patients with advanced solid tumors and exhibits antitumor activity in advanced BCC and relapsed medulloblastoma, both of which are strongly associated with activated hedgehog pathway, as determined by gene expression.
Journal ArticleDOI
Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor
Hans Skvara,Frank Kalthoff,Josef G. Meingassner,Barbara Wolff-Winiski,Heinrich Aschauer,Joseph Kelleher,Xu Wu,Shifeng Pan,Lesanka Mickel,Christopher Schuster,Georg Stary,Ahmad Jalili,Olivier J. David,Corinne Emotte,Ana Antunes,Kristine Rose,Jeremy Decker,Ilene Carlson,Humphrey Gardner,Anton Stuetz,Arthur P. Bertolino,Georg Stingl,Menno A. De Rie +22 more
TL;DR: Treatment with 0.75% LDE225 cream in NBCCS patients was very well tolerated and caused BCC regression, thus potentially offering an attractive therapeutic alternative to currently available therapies for this indication.
Journal ArticleDOI
Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology.
Alison E. M. Vickers,Kristine Rose,Robyn L. Fisher,Muriel Saulnier,Pritam S. Sahota,Philip Bentley +5 more
TL;DR: Cisplatin-induced nephrotoxicity was demonstrated morphologically in rat and human kidney slices, and the associated gene expression and functional changes characterized the cellular pathways involved.
Journal ArticleDOI
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Neil A. O'Brien,M McDermott,Dylan Conklin,Tong Luo,Raul Ayala,Suruchi Salgar,Kevin Chau,Emmanuelle DiTomaso,Emmanuelle DiTomaso,Naveen Babbar,Faye Su,Alex Gaither,Sara A. Hurvitz,Ronald Linnartz,Kristine Rose,Samit Hirawat,Samit Hirawat,Dennis J. Slamon +17 more
TL;DR: These data support the clinical investigation of p110α-selective inhibitors of PI3K, such as alpelisib, in patients with ER+/HER2− breast cancer who have progressed on CDK4/6:ER-based therapies and support the investigation ofPI3K:CDK4:ER triple combination therapy to prevent the onset of resistance to the combination of endocrine therapy plus CDK 4/6 inhibition.